Understanding and overcoming immune evasion in aggressive breast cancer
Characterizing and Overcoming MHC-I-Mediated Immune Evasion in Triple-Negative Breast Cancer
This study is looking at how triple-negative breast cancer hides from the immune system and aims to find new ways to help the immune system fight it better, giving patients a chance to try out new treatments in upcoming trials.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-10902488 on NIH RePORTER |
What this research studies
This research focuses on triple-negative breast cancer (TNBC), a challenging subtype of breast cancer that lacks effective treatment options. The study aims to investigate how TNBC tumors evade the immune system by downregulating important molecules that help the immune system recognize and attack cancer cells. By characterizing these immune-evasive tumors, the researchers hope to develop new combination immunotherapy strategies that can enhance the immune response against TNBC. Patients may have the opportunity to participate in trials testing these innovative treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with triple-negative breast cancer who may benefit from new immunotherapy approaches.
Not a fit: Patients with other subtypes of breast cancer or those who do not have a diagnosis of breast cancer may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and better outcomes for patients with triple-negative breast cancer.
How similar studies have performed: Previous research has shown promise in overcoming immune evasion in various cancers, suggesting that this approach could be effective for triple-negative breast cancer as well.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: O'connell, Dina — Univ of North Carolina Chapel Hill
- Study coordinator: O'connell, Dina
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.